Colchicine in Cardiac Surgery: The COCS Randomized Clinical Trial.
Vladimir A ShvartzTatyana LeSoslan EnginoevMaria SokolskayaArtak IspiryanElena ShvartzDaria NudelNaylyana AraslanovaAndrey PetrosyanSergey DonakanyanIgor ChernovLeo BockeriaElena GolukhovaPublished in: Journal of cardiovascular development and disease (2022)
= 0.028). Thus, there were statistically significant differences between groups in the primary endpoint, thereby confirming the effectiveness of short-term colchicine use for the POAF prevention after coronary artery bypass grafting and/or aortic valve replacement. Also, we detected statistically significant differences between groups in the frequency of side effects to colchicine: diarrhea and abdominal pain were more common in the colchicine group. This clinical trial is registered with ClinicalTrials database under a unique identifier: NCT04224545.
Keyphrases
- coronary artery bypass grafting
- aortic valve replacement
- abdominal pain
- clinical trial
- cardiac surgery
- coronary artery disease
- transcatheter aortic valve implantation
- percutaneous coronary intervention
- aortic valve
- aortic stenosis
- randomized controlled trial
- acute kidney injury
- systematic review
- emergency department
- transcatheter aortic valve replacement
- open label
- left ventricular
- adverse drug
- atrial fibrillation